COVID-19: Vaccines and Therapeutics
The Senate last night voted 49-44 to approve a resolution calling for congressional disapproval of a Centers for Medicare & Medicaid Services rule that required workers in most health care settings that participate in the Medicare and Medicaid programs to be fully vaccinated against COVID-19 by…
The Centers for Disease Control and Prevention today released studies examining the effectiveness of the Pfizer COVID-19 vaccine at preventing emergency department and urgent care visits by children aged 5-17, and reactions to the Pfizer booster in adolescents aged 12-17.
Here are the top medical innovations the Cleveland Clinic sees for 2022, including next-gen of mRNA vaccinology, PSMA-targeted therapy for prostate cancer, novel drug treatment for type 2 diabetes, and artificial intelligence (AI) for early sepsis detection.
On this episode, I talk with Marcus Whitney, co-founder and partner of Jumpstart Health Investors, focused on innovation and investment in health care. Whitney also is founder and general partner of Jumpstart Nova, a venture fund investing in Black-led health care companies.
Hospital leaders say that while the omicron surge has declined, the death toll among children in Louisiana has risen to 21 in February.
The Food and Drug Administration authorized a revised dosing regimen for the combination monoclonal antibody therapy Evusheld when used to prevent COVID-19 in certain patients, citing data showing a higher initial dose may better prevent infection by certain omicron subvariants.
Though 80% of Rhode Islanders have received two doses of COVID-19 vaccine, Care New England says it’s not enough until all eligible are vaccinated and boosted.
AHA Health Systems Leadership Retreat Keynote: A Tapestry of Voices with Anna Deavere Smith. Anna Deavere Smith, Actress, Playwright, Professor, and McArthur Foundation Genius Fellow, shares a range of health care perspectives from those she has interviewed over the years.
The Centers for Disease Control and Prevention said some people may wish to receive their second dose of the Pfizer or Moderna COVID-19 vaccine up to eight weeks after the first, especially males aged 12 to 39.
As part of a national CDC study, Intermountain Healthcare research shows COVID-19 vaccine boosters are highly effectively in preventing hospitalization and death.